Genetic sequencing testing is the laboratory determination of the precise order of nucleotides in DNA or RNA, enabling detection of disease-associated variants, pathogen identification, species verification, and genetic trait analysis. Accredited third-party laboratories apply Sanger sequencing, next-generation sequencing (NGS), and long-read technologies under internationally recognized frameworks such as ISO 15189, ISO/IEC 17025, and ISO 20395 to deliver accurate, reportable results. This guide explains the sequencing workflow, sample requirements, testing items, analytical methods, and applications across clinical, food, agricultural, and biopharmaceutical fields.
Technical Overview
Genetic sequencing testing determines the exact order of nucleotide bases—adenine (A), cytosine (C), guanine (G), and thymine (T), or uracil (U) in RNA—within a DNA or RNA molecule. By decoding this sequence information, laboratories can identify single nucleotide variants (SNVs), insertions and deletions (InDels), copy number variants (CNVs), structural variants (SVs), gene fusions, epigenetic modifications, and species- or strain-specific microbial markers. The technology underpins clinical molecular diagnostics, hereditary disease risk assessment, oncology precision medicine, infectious disease surveillance, food authenticity verification, and agricultural breeding programs.
A complete sequencing project typically follows a standardized workflow: sample accessioning with chain-of-custody documentation, nucleic acid extraction, quality control and quantification, library preparation and target enrichment, sequencing on an appropriate platform, bioinformatic processing, variant or species annotation, and clinical or technical interpretation in a final report. Competent laboratories operate under quality management frameworks such as ISO 15189 for medical laboratories and ISO/IEC 17025 for general testing laboratories, with method performance evaluated according to ISO 20395. Pre-examination handling of specimens is guided by the ISO 20166 series, nucleic acid quality evaluation follows practices aligned with GB/T 37874, and high-throughput sequencing procedures are further supported by references such as GB/T 30989. Bioinformatics software used in regulated contexts is commonly developed under IEC 62304 and ISO 13485, and information security controls are aligned with ISO 27001.
Testing Samples
Sequencing laboratories accept a broad range of biological materials. The suitability, volume, handling, and transport requirements vary by sample type and intended assay.
Blood and Bone Marrow Samples
Peripheral blood collected in EDTA anticoagulant tubes (typically 2–5 mL) is the standard source of germline genomic DNA for hereditary disease testing, pharmacogenomics, and identity analysis. Heparinized tubes should be avoided because heparin inhibits the polymerases used in amplification and library preparation. Bone marrow aspirates (1–3 mL in EDTA) are the preferred material for hematologic malignancy profiling. Whole blood and marrow samples should be transported at 2–8 °C and processed within 48–72 hours of collection.
Saliva and Buccal Swab Samples
Saliva collected into tubes containing DNA-stabilizing reagents and air-dried buccal swabs provide non-invasive alternatives for germline testing, carrier screening, and kinship analysis. These matrices generally yield lower quantities of human DNA and may contain microbial DNA background, which must be considered when designing assays and interpreting results.
Fresh-Frozen and FFPE Tissue Samples
Solid tumor profiling relies on fresh-frozen or formalin-fixed paraffin-embedded (FFPE) tissue. Formalin fixation causes cross-linking, DNA fragmentation, and cytosine deamination artifacts, so FFPE specimens are assessed for amplifiability and fragment integrity (for example, DV200-type metrics) before sequencing. A minimum tumor cellularity of approximately 20% is typically required for somatic variant detection, and typical DNA input requirements range from 50–200 ng, with validated low-input protocols available for limited biopsies.
Plasma and Liquid Biopsy Samples
Cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) analysis requires 10–20 mL of blood collected in EDTA tubes with prompt double centrifugation within 2–4 hours, or in specialized cell-stabilizing tubes processed within 48–72 hours. cfDNA is used for non-invasive tumor genotyping, minimal residual disease (MRD) monitoring, and non-invasive prenatal testing (NIPT).
Prenatal and Reproductive Samples
Amniotic fluid (5–10 mL), chorionic villus samples, cord blood, and products of conception are accepted for fetal karyotype-level analysis and monogenic disease testing. Embryonic trophectoderm biopsies are analyzed for preimplantation genetic testing (PGT), and maternal cell contamination assessment is routinely performed as an integral quality control step.
Pathogen and Microbiological Samples
Sputum, bronchoalveolar lavage fluid (BALF), cerebrospinal fluid (CSF), blood, sterile-site fluids, respiratory or wound swabs, stool, and environmental swabs are accepted for metagenomic next-generation sequencing (mNGS), 16S/ITS amplicon profiling, and whole-genome sequencing of isolated strains for typing and antimicrobial resistance gene detection. Host DNA depletion techniques may be applied to improve microbial sensitivity.
Agricultural, Food, and Environmental Samples
Plant leaves and seeds, animal tissue, processed meat, dairy products, honey, herbal products, soil, and water samples are used for species identification, authenticity verification, GMO event screening, variety identification, marker-assisted breeding, and microbiome characterization. Processed foods often require adapted extraction chemistries to remove PCR and sequencing inhibitors.
Testing Items
Common testing items and analytical deliverables offered by accredited third-party laboratories include:
- Nucleic acid quality control: fluorometric concentration measurement, purity assessment (A260/280 ratio of approximately 1.8 for DNA; A260/230 ratio of 2.0–2.2), and integrity evaluation (DIN/RIN values for RNA, DV200-type metrics for FFPE, agarose gel or capillary electrophoresis profiles).
- Whole genome sequencing (WGS): comprehensive SNV, InDel, CNV, and SV detection across the entire genome, typically at 30× mean depth for germline applications.
- Whole exome sequencing (WES): capture of the protein-coding exome (approximately 45–60 Mb), commonly at 100× mean target depth for germline analysis and higher depths for somatic applications.
- Targeted gene panel sequencing: focused hotspot panels or custom panels covering tens to hundreds of genes, typically at 500–1000× mean depth, with detection of variants down to approximately 0.5–1% variant allele frequency when error-corrected chemistries are used.
- RNA sequencing: whole-transcriptome and targeted RNA assays for fusion transcript detection and expression profiling; RNA samples with RIN values of 7 or above are generally recommended.
- Metagenomic next-generation sequencing (mNGS): unbiased detection of bacterial, viral, fungal, and parasitic nucleic acids directly from clinical specimens.
- 16S rRNA and ITS amplicon sequencing: microbial community composition profiling for microbiome studies.
- Mitochondrial genome sequencing: full-length mitogenome analysis (approximately 16.6 kb) with heteroplasmy quantification.
- Methylation and epigenetic sequencing: bisulfite-based or enzymatic conversion methods for DNA methylation profiling.
- Sanger sequencing: single-amplicon sequencing for verification of key findings, family segregation studies, and targeted gene analysis.
- STR profiling: short tandem repeat analysis for human cell line authentication and identity testing.
Standard sequencing quality metrics reported with these items include Q30 base quality (typically ≥85–90% of bases), mapping rate (≥95–98%), duplication rate, on-target rate (≥70–90% for capture-based enrichment and higher for amplicon-based enrichment), mean target coverage, coverage uniformity, and GC bias.
Testing Methods
Sample Receipt, Extraction, and Quality Control
Upon accessioning, samples are verified against the chain of custody, and nucleic acids are extracted using validated silica-membrane or magnetic-bead chemistry. Concentration is measured fluorometrically, purity is assessed by UV spectrophotometry, and integrity is evaluated by agarose gel electrophoresis or microfluidic capillary electrophoresis. Acceptance criteria follow the pre-examination guidance of the ISO 20166 series and nucleic acid quality evaluation practices aligned with GB/T 37874; samples that fail acceptance thresholds trigger re-extraction or consultation with the client before proceeding.
Library Preparation and Target Enrichment
DNA is fragmented by enzymatic or ultrasonic methods, end-repaired, A-tailed, ligated with indexed adapters, and amplified. Target enrichment is performed either by hybridization capture, which supports broad panels and CNV detection, or by multiplex amplicon-based enrichment, which is faster, requires lower input, and performs well with FFPE-derived DNA. Unique molecular identifiers (UMIs) are frequently incorporated to suppress amplification and sequencing errors and to enable error-corrected detection of low-frequency variants.
Sanger Sequencing
First-generation chain-termination sequencing uses fluorescently labeled dideoxynucleotides and capillary electrophoresis separation to generate reads of approximately 600–1000 bp. It remains the confirmatory gold standard for variant verification and is well suited to germline heterozygous variant detection, with typical analytical sensitivity for variants at 15–20% variant allele frequency or above.
Short-Read NGS (Sequencing by Synthesis)
Clonally amplified libraries are sequenced on flow-cell or semiconductor platforms using cyclic synthesis chemistry with reversible terminators or pH-based detection. Paired-end reads of 100–300 bp are generated at scales from millions to billions of reads per run, with per-base quality scoring. This technology supports WGS, WES, targeted panels, RNA-seq, and metagenomic applications and is the current backbone of high-throughput sequencing services.
Long-Read (Third-Generation) Sequencing
Single-molecule real-time (SMRT) and nanopore-based platforms produce individual reads ranging from 10 kb to more than 1 Mb. Long reads resolve large structural variants, repeat expansions, complex genomic regions, phased haplotypes, and native base modifications such as methylation. Consensus and high-accuracy modes are used to compensate for higher raw per-read error rates.
Bioinformatic Analysis and Interpretation
The analytical pipeline comprises raw data quality control and adapter trimming, alignment to a reference genome such as GRCh38, duplicate marking, base quality recalibration, variant calling for SNVs, InDels, CNVs, SVs, and fusions, and annotation against curated public databases such as ClinVar, gnomAD, and COSMIC. Variants are filtered by population frequency, predicted functional consequence, and domain-specific criteria, and clinical variants are classified according to internationally recognized guidelines such as the ACMG/AMP framework. For metagenomic samples, reads are taxonomically classified against curated microbial reference databases after human sequence subtraction, and results are interpreted in the context of colonization and background contamination.
Method Validation and Quality Assurance
Sequencing methods are validated before routine use for accuracy, precision (intra-run and inter-run repeatability), analytical sensitivity and limit of detection, analytical specificity, and reportable range, consistent with ISO 20395 and laboratory accreditation requirements under ISO 15189 and ISO/IEC 17025. Routine quality assurance includes positive, negative, and no-template controls; run-level performance metrics against predefined acceptance thresholds; periodic proficiency testing or interlaboratory comparison; and contamination control monitoring. Data security and participant privacy are managed under information security practices aligned with ISO 27001.
Applications
Genetic sequencing testing supports a wide spectrum of clinical and industrial use cases, including:
- Hereditary and rare disease diagnostics: WES and WGS for pediatric, neurodevelopmental, and undiagnosed disease workups, including trio analysis and segregation studies.
- Oncology precision medicine: companion diagnostics for targeted therapy selection, tumor mutational burden (TMB), microsatellite instability (MSI), and homologous recombination deficiency (HRD) assessment for immunotherapy and PARP inhibitor decisions, and ctDNA-based MRD monitoring.
- Reproductive health: non-invasive prenatal testing (NIPT) for fetal aneuploidy, invasive prenatal diagnosis, preimplantation genetic testing (PGT), and expanded carrier screening.
- Infectious disease: mNGS for unexplained infections in CSF, BALF, and blood; genomic epidemiology for outbreak tracing; whole-genome strain typing; and antimicrobial resistance gene profiling.
- Pharmacogenomics: CYP450 family and HLA genotyping to guide drug selection, dosing, and hypersensitivity risk assessment.
- Food authenticity and safety: meat species identification, GMO event screening, adulteration detection in honey and herbal products, and foodborne outbreak source tracing.
- Agriculture and breeding: variety identification, seed purity testing, marker-assisted and genomic selection, and agronomic trait gene discovery.
- Environmental and microbiome research: 16S/ITS community profiling of soil, water, and gut ecosystems, and environmental DNA (eDNA) biodiversity monitoring.
- Biopharmaceutical quality control: STR-based cell line authentication, vector copy number and plasmid sequence confirmation for cell and gene therapy products, and adventitious agent testing.
- Forensic and identity testing: STR sequencing, mitochondrial DNA analysis, and kinship determination.
FAQ
What is the typical turnaround time for genetic sequencing testing?
Sanger sequencing of single genes generally completes within 3–7 working days, targeted NGS panels within 7–10 working days, WES or WGS within 2–4 weeks, and mNGS for critical infectious disease cases within 24–72 hours. Complex bioinformatic analysis, confirmatory testing, or re-sequencing of low-quality samples may extend these timelines.
How much DNA or sample is required?
Typical input requirements are 50–200 ng of DNA for targeted panel sequencing, 100–500 ng for WES or WGS, and 10–50 ng per reaction for Sanger sequencing, with cfDNA extracted from 10–20 mL of blood for liquid biopsy applications. Validated low-input and ultra-low-input protocols exist, and specific requirements should be confirmed with the testing laboratory based on the selected assay.
Can FFPE tissue samples be used for sequencing?
Yes. FFPE tissue is a major source of tumor DNA for somatic profiling. Because fixation causes fragmentation and artifactual C>T substitutions, laboratories first assess DNA quality using amplifiability or fragment-distribution metrics, often favor amplicon-based enrichment with UMI error correction for compromised specimens, and apply bioinformatic filtering to remove deamination artifacts.
What is the difference between WGS, WES, and targeted panel sequencing?
WGS covers the entire genome of approximately 3 Gb, including noncoding regions; WES covers the protein-coding exome, roughly 1–2% of the genome where most known pathogenic variants reside, at lower cost; and targeted panels focus on tens to hundreds of clinically actionable genes at very high depth, enabling detection of low-frequency somatic variants. Selection depends on the clinical or technical question, budget, sample quality, and turnaround requirements.
How is accuracy and data quality ensured?
Accuracy is ensured through method validation in accordance with ISO 20395, operation within accredited quality systems under ISO 15189 or ISO/IEC 17025, run-level quality metrics such as Q30, mapping rate, and coverage depth with predefined acceptance thresholds, inclusion of reference controls, orthogonal confirmation of key findings by Sanger sequencing where appropriate, and ongoing participation in proficiency testing programs.
Which deliverables are provided with the report?
A standard report includes the methodology summary, sequencing quality metrics, results such as annotated variants, species classifications, or fusion calls, interpretation with clinical or technical context, assay limitations, and references. Raw and analyzed data files, including FASTQ, BAM, and VCF formats, are supplied according to the service agreement, with data retention periods defined contractually.
How is genetic data privacy protected?
Specimens and datasets are de-identified using coded accessions, informed consent is obtained for human genetic testing, and information security controls are aligned with ISO 27001. Data are shared only in accordance with the consent scope and applicable regulations, and retention or destruction follows the terms agreed with the client.